Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Novo Nordisk A/S stock (NVO)

Buy Novo Nordisk A/S stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $117.20 – an increase of 0.62% over the previous week. Novo Nordisk A/S employs 69,260 staff and has a trailing 12-month revenue of around $258 billion.

Our top picks for where to buy Novo Nordisk A/S stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Novo Nordisk A/S stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – NVO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Novo Nordisk A/S stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
eToro
Finder Score: 4 / 5: ★★★★★
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.9%
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
No commission stock, ETF and options trades, with 4.9% interest on your options account balance and no options contract fees.
Robinhood
Finder Score: 4.4 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Novo Nordisk A/S stock price (NYSE: NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk A/S shares at a glance

Information last updated 2024-10-09.
Latest market close$117.20
52-week range$91.93 - $147.59
50-day moving average $129.95
200-day moving average $127.32
Wall St. target price$142.97
PE ratio 39.7288
Dividend yield $9.9 (1.23%)
Earnings per share (TTM) $2.95

Is it a good time to buy Novo Nordisk A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novo Nordisk A/S price performance over time

Historical closes compared with the close of $117.2 from 2024-10-08

1 week (2024-10-03) 1.84%
1 month (2024-09-10) -9.69%
3 months (2024-07-10) -17.89%
6 months (2024-04-10) -6.19%
1 year (2023-10-10) 26.01%
2 years (2022-10-10) 12.86%
3 years (2021-10-08) 19.13%
5 years (2019-10-10) 136.47%

Is Novo Nordisk A/S stock undervalued or overvalued?

Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk A/S's P/E ratio

Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Novo Nordisk A/S shares trade at around 40x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk A/S's PEG ratio

Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7905. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novo Nordisk A/S's EBITDA

Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $126.6 billion.

The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.

Novo Nordisk A/S financials

Revenue TTM $258 billion
Operating margin TTM 46.48%
Gross profit TTM $148.5 billion
Return on assets TTM 22.8%
Return on equity TTM 88.57%
Profit margin 34.84%
Book value $25.24
Market Capitalization $522.1 billion

TTM: trailing 12 months

Novo Nordisk A/S share dividends

49%

Dividend payout ratio: 49.36% of net profits

Recently Novo Nordisk A/S has paid out, on average, around 49.36% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.23% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.23% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $9.9 per share.

While Novo Nordisk A/S's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk A/S may be investing much of the rest of its net profits in future growth.

Novo Nordisk A/S's most recent dividend payout was on 25 August 2024. The latest dividend was paid out to all shareholders who bought their shares by 15 August 2024 (the "ex-dividend date").

Have Novo Nordisk A/S's shares ever split?

Novo Nordisk A/S's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.

Novo Nordisk A/S share price volatility

Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $91.928 up to $147.5933. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.148. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).

Novo Nordisk A/S overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc.

Frequently asked questions

null
What percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.004% of Novo Nordisk A/S shares are held by insiders and 10.203% by institutions.
How many people work for Novo Nordisk A/S?
Latest data suggests 69,260 work at Novo Nordisk A/S.
When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December.
Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Alle 1, Bagsvaerd, Denmark, 2880
What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056
What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site